PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22731793-0	2012	Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy.	1,5-anhydroglucitol	10-29	insulin	Homo sapiens	141-148	
2244184-5	1990	In insulin-dependent (type 1) diabetes with a long history of disease the concentration of 1,5-anhydroglucitol remains low in spite of improvement of glycaemic control by intensification of treatment, whereas in non-insulin dependent (type 2) diabetes the concentration gradually increases towards normal levels concomitantly with improvement in glycaemic control.	1,5-anhydroglucitol	91-110	insulin	Homo sapiens	3-10	
34167955-0	2021	Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes.	1,5-anhydroglucitol	7-26	insulin	Homo sapiens	58-65	
34167955-3	2021	This study aimed to explore the relationship between saliva 1,5-AG and insulin secretion function and insulin sensitivity.	1,5-anhydroglucitol	60-66	insulin	Homo sapiens	71-78	
34167955-3	2021	This study aimed to explore the relationship between saliva 1,5-AG and insulin secretion function and insulin sensitivity.	1,5-anhydroglucitol	60-66	insulin	Homo sapiens	102-109	
35512857-0	2022	Effects of 1,5-anhydro-D-glucitol on insulin secretion both in in vitro and ex vivo pancreatic preparations.	1,5-anhydroglucitol	11-33	insulin	Homo sapiens	37-44	
35512857-3	2022	1,5-anhydro-D-glucitol (1,5-AG) is found in foods, and exists in humans and rodents; however, whether 1,5-AG stimulates insulin secretion remains unclear.	1,5-anhydroglucitol	0-22	insulin	Homo sapiens	120-127	
35512857-3	2022	1,5-anhydro-D-glucitol (1,5-AG) is found in foods, and exists in humans and rodents; however, whether 1,5-AG stimulates insulin secretion remains unclear.	1,5-anhydroglucitol	102-108	insulin	Homo sapiens	120-127	
35512857-4	2022	This study aimed to assess the effects of short-term 1,5-AG stimulation on insulin secretion in both ex vivo and in INS-1E (rat-derived) cells in vitro.	1,5-anhydroglucitol	53-59	insulin	Homo sapiens	75-82	
27246285-0	2016	1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy.	1,5-anhydroglucitol	0-22	insulin	Homo sapiens	98-105	
6360421-0	1984	Serum 1,5-anhydroglucitol concentration in diabetic patients receiving a continuous subcutaneous infusion of insulin.	1,5-anhydroglucitol	6-25	insulin	Homo sapiens	109-116	
6345028-3	1983	1-Deoxyglucose was generally not detectable in plasmas of diabetic patients before they received insulin; it was measurable in the patients who had received insulin, although its concentration was low compared with that of healthy subjects.	1,5-anhydroglucitol	0-14	insulin	Homo sapiens	97-104	
6345028-3	1983	1-Deoxyglucose was generally not detectable in plasmas of diabetic patients before they received insulin; it was measurable in the patients who had received insulin, although its concentration was low compared with that of healthy subjects.	1,5-anhydroglucitol	0-14	insulin	Homo sapiens	157-164	
26172028-9	2015	All levels of measurable C-peptide were responsive to acute fluctuations in blood glucose levels as assessed by 1,5-Anhydroglucitol (P < 0.0001).	1,5-anhydroglucitol	112-131	insulin	Homo sapiens	25-34	
19254570-2	2009	Here, we evaluated the role of PGC-1beta in the pathogenesis of fructose-induced insulin resistance by using an antisense oligonucletoide (ASO) to knockdown PGC-1beta in liver and adipose tissue.	1,5-anhydroglucitol	139-142	insulin	Homo sapiens	81-88	
22421598-0	2012	Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.	1,5-anhydroglucitol	21-40	insulin	Homo sapiens	57-64	
19620188-12	2009	HbA1c and 1,5-anhydroglucitol are excellent predictors of T2DM in insulin-resistant obese children.	1,5-anhydroglucitol	10-29	insulin	Homo sapiens	66-73